Pediatric heart failure drug Entresto gains FDA nod

05:43 EDT 3 Oct 2019 | SmartBrief

Novartis' Entresto, or sacubitril and valsartan, gained the FDA's approval as a treatment for pediatric patients aged 12 mont -More

Original Article: Pediatric heart failure drug Entresto gains FDA nod


More From BioPortfolio on "Pediatric heart failure drug Entresto gains FDA nod"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...